By Lithin Reddy
Published: Friday, Jan 28, 2022, 1:30 [IST]
The company said its revenue from operations is up 8% YoY, down 8% QoQ. Gross Margin at 53.8%, compared to 53.4% in the previous quarter. EBITDA at Rs 1,266 Crores, up 7% YoY, down 19% QoQ, Profit before tax at Rs 971 crores, down 23% QoQ, Profit after tax at Rs 707 crores, down 29% QoQ. R&D expenses at Rs 416 crores, which is 7.8% of revenues.
- Revenue at Rs 5,320 Cr, Up 8% YoY and down 8% QoQ.
- Gross Margina at 53.8%, compared to 53.4% in previous quarter.
- R&D expenses at Rs 416 crores, which is 7.8% of revenues.
- EBITDA at 1,266 crores, up 7% YoY, down 19% QoQ.
- Profit after tax at Rs 707 crores, up 2,432% YoY, down 29% QoQ.
Sales Mix
Revenues from Global Genrics
Revenues from global generics is at 44.5 billion.
YoY growth of 9% was primarily driven by new product launches and higher sales volume and QoQ decline of 6% was due to lower volumes and price erosion in some of Dr. Reddy’s products.
Revenues from North America
Revenues from North America at Rs 18.6 billion.
Year-on-year growth of 7%, driven by new products launch, increase in volumes of base business, and a favorable forex trade rate, which was partially offset by price erosion.
Q0Q decline of 1%, primarily due to price erosion in some of Dr. Reddy’s products. the company launches 4 new products in the U.S during the quarter. These products are Carmustine Injection, Ephedrine Sulphate injection, Valsartan tablets, and Venlafaxine ER tablets.
Revenues from Europe
Revenues from Europe at Rs 4.1 billion.
Year-on-year and QoQ decline of 2% each, which was primarily due to price erosion in some of Dr. Reddy’s existing products, partially offset by volume traction in the base business and sales from new products launched.
Reveues from India
Revenues from India at Rs 10.3 billion.
Year-on-year growth of 7% which was on account of an increase in sales prices of some of the existing products and revenues from new products launched, offset partially by a decrease in the sales volume of covid-related products.
QoQ decline of 10%, primarily due to reduction in sales volumes of covid related products.
Othet Key Highlights
EBITDA at Rs 12.7 billion and the EBITDA margin is 23.8%.
Capital expenditure is at Rs. 4.1 billion.
Free cash flow is at Rs 12.7 billion.
ROCE is at 23.9%.
